Literature DB >> 2475996

Azelaic acid: mode of action at cellular and subcellular levels.

I Galhaup1.   

Abstract

Azelaic acid (AZA) has been reported to have an inhibitory effect on DNA synthesis of melanoma cell lines. In order to elucidate the mechanism(s) underlying this inhibitory effect, I elected to study the effects of AZA and, for control purposes, adipic acid (ADA) on DNA synthesis rate of nuclei isolated from melanoma cells and keratinocytes cultured in the presence of different concentrations of the dicarboxylic acids. Before doing so, I found, by autoradiography, that [3H]AZA is incorporated into the nuclei in a time-dependent manner. AZA, and to a lesser extent ADA, caused a dose-dependent inhibition of DNA synthesis, regardless of whether these substances were present in cell cultures before isolation of nuclei, or were incubated with already isolated nuclei. In searching for the target for this inhibitory effect on nuclear DNA synthesis, I found that AZA, and to a lesser extent ADA, is a potent inhibitor of both bacterial DNA polymerase and of multienzyme complexes isolated from cultured melanoma cells and keratinocytes. These data suggest that the inhibitory effect of the dicarboxylic acids AZA and ADA on DNA synthesis of several cell lines is due to the interference of these substances with the activation of enzymes (e.g. DNA polymerases) required for DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475996

Source DB:  PubMed          Journal:  Acta Derm Venereol Suppl (Stockh)        ISSN: 0365-8341


  2 in total

Review 1.  Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders.

Authors:  A Fitton; K L Goa
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  A systematic in silico search for target similarity identifies several approved drugs with potential activity against the Plasmodium falciparum apicoplast.

Authors:  Nadlla Alves Bispo; Richard Culleton; Lourival Almeida Silva; Pedro Cravo
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.